Goldman Sachs Downgrades Jazz Pharmaceuticals (JAZZ) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $214.00 -0.3%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Sell with a price target of $128.00.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $136.80 yesterday.
You May Also Be Interested In
- Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA
- H.C. Wainwright Downgrades Avalo Therapeutics Inc. (AVTX) to Neutral
- Jazz Pharmaceuticals (JAZZ) PT Lowered to $314 at Morgan Stanley
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
